Question 1

What is CDX-622?

Accepted Answer

CDX-622 is a Other.

Question 2

How often does CDX-622 appear in global news?

Accepted Answer

Tracked across 1 news events drawn from 6 articles.

Question 3

When was CDX-622 first tracked by Ergen?

Accepted Answer

First tracked on Jun 10, 2026.

Question 4

When was CDX-622 last mentioned in news?

Accepted Answer

Last active on Jun 10, 2026.

Question 5

What is CDX-622's current news sentiment?

Accepted Answer

Aggregate sentiment score: 70 on a -100 to +100 scale (negative = critical coverage, positive = favorable coverage).

Question 6

How prominent is CDX-622 in global news coverage?

Accepted Answer

Attention score of 4, derived from article volume and coverage intensity across 1 events.

Question 7

What is the most recent event involving CDX-622?

Accepted Answer

Celldex Presents Barzolvolimab, CDX-622 Data (Jun 10, 2026, 6 articles).

Question 8

How did the "Celldex Presents Barzolvolimab, CDX-622 Data" event impact CDX-622?

Accepted Answer

CDX-622 is a novel bispecific antibody from Celldex Therapeutics, with first-in-human Phase 1 results being presented, showing potential for enhanced therapeutic benefit in inflammatory and fibrotic disorders.

Question 9

How is this data collected?

Accepted Answer

Ergen aggregates thousands of global news sources and extracts structured events, entities, and relationships with sentiment and attention metrics. Pages are daily static snapshots from the platform's live database.